Work

OC 14.3 A Novel Strategy to Combat the Procoagulant Phenotype in Immune Thrombotic Thrombocytopenia using 12-LoX Inhibition

Year: 2023

Type: article

Abstract: Background: Immune thrombotic thrombocytopenia (ITT) disorders, including heparin-induced thrombocytopenia (HIT), are caused by IgG immune complexes that activate platelets through Fc Receptor for IgG IIA (FcγRIIA).ITTs, characterized by platelet-fibrin thrombi, are common and inadequately treated.Thrombotic events remain high following the standard of care treatment with anticoagulants, while increasing risk of bleeding complications.Aims: This study sought to investigate a novel approach to treatment of ITT.Recent reports demonstrate increased procoagulant activity in ITT.However, these reports required ex vivo analysis, and in vivo relevance remains unclear.Methods: Using human and mouse model systems, we investigated the cooperativity of protease activated receptors (PARs) and FcγRIIA in ITT.We challenged humanized FcγRIIA transgenic mice with or without endogenous

Source: Research and Practice in Thrombosis and Haemostasis

DOI: 10.1016/j.rpth.2023.100539